A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the
clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Financial Summary
| Share Statistics | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $35.0 | $259.1 | 13% |
|
| Shares Out (Mil) | 7.3 | 54.3 | 17% |
|
| Institutional Ownership | 78.2% | 92.8% | 47% |
|
| Float (Mil) | 7.9 | 42.0 | 16% |
|
| Beta | 1.53 | 0.95 | 83% |
|
| Avg Daily Volume (000s) | 154 | 637 | 40% |
|
| Price Change (52-week) |
(57.3%) | 52.5% | 14% |
|
| Growth | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (45.7%) | (10.1%) | 8% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($31) | ($43) | 20% |
|
| EPS (TTM) | ($9.657) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($31) | ($32) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $13 | $175 | 9% |
|
| Valuation | BCTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.21 | 2.54 | 31% |
|
| P/E | na | 18.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BCTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (139.2%) | (47.5%) | 4% |
|
| ROE | (168.2%) | (54.9%) | 5% |
|
| Liabilities to Assets | 13.5% | 29.4% | 8% |
|
| F-Score | 3 | 3 | 18% |
|
BriaCell Therapeutics Corp. did not pass any screens on 9/23/2026.
